Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing to Identify an Immunogenic Cell Death-Related 5-Gene Prognostic Signature in Hepatocellular Carcinoma
DOI: https://doi.org/10.2147/jhc.s449419
2024-05-17
Journal of Hepatocellular Carcinoma
Abstract:Liqun Peng, 1, 2 Shaohua Xu, 3 Jian-Liang Xu 4 1 Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China; 2 Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Wuhan, People's Republic of China; 3 Department of Clinical Laboratory, Center for Gene Diagnosis & Program of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China; 4 Department of Hepatobiliary Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China Correspondence: Jian-Liang Xu, Department of Hepatobiliary Surgery, the Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou, 510630, People's Republic of China, Tel +86-13580575810, Fax +8620-85253178, Email Shaohua Xu, Department of Clinical Laboratory, Center for Gene Diagnosis & Program of Clinical Laboratory, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, People's Republic of China, Email Introduction: Immunogenic cell death (ICD) can enhance the potency of immunotherapy in cancer treatment. Nevertheless, it is ambiguous how ICD-related genes (ICDRGs) contribute to hepatocellular carcinoma (HCC). Methods: Single-cell RNA sequencing (scRNA-seq) data were used to distinguish malignant cells from normal cells in the HCC tumor microenvironment(TME). Bulk RNA sequencing data was employed to acquire the landscape of the 33 ICDRGs. Unsupervised clustering identified two ICD molecular subtypes. The cellular infiltration characteristics and biological behavior in different subtypes were analyzed by ssGSEA. Subsequently, differentially expressed genes (DEGs) between the two subtypes were determined, based on which patients were classified into three gene clusters. Then, the prognostic model was constructed by Lasso-Cox analysis. Finally, we investigated the expression of risk genes in cancer cell line encyclopedia (CCLE) and validated the function of NKX3-2 in vitro experiments. Results: ICD scores and ICDRGs expression in malignant cells were significantly lower than in normal cells by scRNA-seq analysis. ICD-high subtype was characterized by ICD-related gene overexpression and high levels of immune infiltration abundance and immune checkpoints; Three DEGs-related gene clusters were likewise strongly linked to stromal and immunological activation. In the ICD-related prognostic model consisting of NKX3-2, CHODL, MMP1, NR0B1, and CTSV, the low-risk group patients had a better endpoint and displayed increased susceptibility to immunotherapy and chemotherapeutic drugs like 5-Fluorouracil, afatinib, bortezomib, cediratinib, lapatinib, dasatinib, gefitinib and crizotinib. Moreover, NKX3-2 amplification in HCC samples has been verified by experiments, and its disruption suppressed the proliferation and invasion of tumor cells. Conclusion: Our study highlighted the potential of the ICDRGs risk score as a prognostic indicator to aid in the accurate diagnosis and immunotherapy sensitivity of HCC. Keywords: Hepatocellular carcinoma, prognostic model, immunotherapy, immunogenic cell death Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer in the world, and its morbidity and mortality rates continue to rise. 1 Recently, despite the development of new early screening and treatment methods for HCC, 2–4 the prognosis of HCC patients is still dismal. 5,6 In addition, the selection of treatment criteria and identification of high-risk patients remains ambitious owing to individual heterogeneity. Consequently, there is a necessity to discover novel prognostic biomarkers for HCC and to guide individualized treatment. Clinical trials for advanced HCC employing immunotherapy represented by immune checkpoint inhibitors (ICIs) have recently shown encouraging results. 7 However, the highly heterogeneous and suppressive characteristics of the immune TME of HCC substantially restrict the therapeutic efficacy. 8,9 To enhance the effectiveness of immunotherapy and the prognosis of patients, it is crucial to reshape the tumor microenvironment of HCC. Immunogenic cell death (ICD) is a novel model of cell death that increases the immunogenicity of cancer cells and activates the body's anti-tumor immunity. 10 A variety of triggers and anti-tumor treatments can induce ICD, including chemotherapy, 11 radiotherapy, 12 extracorporeal phototherapy, 13 photodynamic therapy, 14 lysoviral therapy, 15 and targeted therapy. 16 ICD is manifested by the induced stim -Abstract Truncated-
oncology